Relapsed and Refractory T-cell Lymphoma
1 clinical trials · Condition
◉ Watch Relapsed and Refractory T-cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma (NCT02309580) | Memorial Sloan Kettering Cancer Center | 2015-01-01 |
Track Relapsed and Refractory T-cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.